Return to homepagePandemic Pact

Examining Whether Early Aggressive Therapy Can Prevent or Delay Disability in People with Multiple Sclerosis: the TREAT-MS Study

  • Funded by Patient-Centered Outcomes Research Institute
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $494,744

  • Funder

    Patient-Centered Outcomes Research Institute

  • Principal Investigator

    MD. Ellen M Mowry

  • Research Location

    United States of America

  • Lead Research Institution

    Johns Hopkins University

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The enhancement seeks to evaluate whether patients with multiple sclerosis (MS) enrolled in the TREAT-MS study delayed or altered the schedule of planned treatment with disease-modifying therapies during the COVID-19 pandemic and whether any delays varied across treatment approach (early intensive versus escalation approach). Further, the study team will determine whether variations in treatment schedule were associated with a higher likelihood of breakthrough disease activity and/or worsening MS symptoms. The team will also examine whether patients with MS treated with higher efficacy versus traditional therapies differ in their risk of severe COVID-19 infection or mortality.